---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-036819"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-24T23:46:15.671202+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Q32 Bio Q4 2024 net loss $14.2M; cash $78M funds into 2H2026; bempikibart AA data encouraging

## Summary
- Cash and cash equivalents $78.0M as of Dec 31, 2024, expected to fund operations into 2H'26.
- Net loss $14.2M ($1.16 per share) for Q4 2024 vs $27.1M ($76.39) in Q4 2023.
- SIGNAL-AA Part B dosing on track for 1H'25; topline data expected 1H'26.
- Phase 2a Part A data presented at AAD showed durable responses post-treatment (median follow-up 41 weeks).
- Bempikibart well-tolerated; no grade 3+ related AEs or related viral infections.

## SEC filing metadata
- accession: 0000950170-25-036819
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000095017025036819/0000950170-25-036819-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000095017025036819/qttb-20250311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-036819
- JSON: https://secwatch.observer/filing/0000950170-25-036819.json
- Plain text: https://secwatch.observer/filing/0000950170-25-036819.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.